| __timestamp | Taro Pharmaceutical Industries Ltd. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 91733000 | 381287000 |
| Thursday, January 1, 2015 | 87644000 | 452612000 |
| Friday, January 1, 2016 | 92365000 | 316800000 |
| Sunday, January 1, 2017 | 85656000 | 330100000 |
| Monday, January 1, 2018 | 88196000 | 265800000 |
| Tuesday, January 1, 2019 | 89971000 | 336200000 |
| Wednesday, January 1, 2020 | 93413000 | 423900000 |
| Friday, January 1, 2021 | 91355000 | 467000000 |
| Saturday, January 1, 2022 | 113676000 | 487000000 |
| Sunday, January 1, 2023 | 198366000 | 477100000 |
| Monday, January 1, 2024 | 218935000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. United Therapeutics Corporation and Taro Pharmaceutical Industries Ltd. have taken different paths in this regard over the past decade. From 2014 to 2023, United Therapeutics consistently reported higher SG&A expenses, peaking at nearly 487% more than Taro's in 2022. However, Taro's SG&A costs surged by 92% from 2022 to 2023, indicating a strategic shift or increased operational costs. Despite United Therapeutics' higher expenses, their consistent growth suggests a robust strategy in leveraging these costs for expansion. Meanwhile, Taro's recent spike raises questions about future financial strategies. As we look to 2024, with data still emerging, the pharmaceutical industry will be keenly observing how these giants balance cost management with growth ambitions.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.